EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")
Change of Adviser
EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed global diagnostics business , announces Singer Capital Markets as sole broker to the Company. Singer Capital Markets also continues to act as Nominated Adviser.
EKF Diagnostics Holdings plc |
|
Mike Salter, CEO / Marc Davies, CFO |
Tel: +44 (0)29 2071 0570 |
|
|
Singer Capital Markets (Nominated Adviser & Broker) |
Tel: +44 (0)20 7496 3000 |
Aubrey Powell / George Tzimas / Oliver Platts |
|
|
|
Walbrook PR Limited |
Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com |
Paul McManus / Lianne Applegarth |
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303 |
About EKF Diagnostics Holdings plc ( www.ekfdiagnostics.com )
EKF is a leading global diagnostics business with custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. EKF is focussed on the following areas:
Point-of-Care |
Providing a portfolio of Point-of-Care analysers and consumables, particularly for use in the area of Hematology and Diabetes, for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF has an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries.
|
Central Laboratory |
Clinical chemistry, Small lab analysers, Centrifuges Beta-Hydroxybutyrate (β-HB) LiquiColor , Glycated Albumin, Glycated Serum Protein, Nitro-tab, Procalcitonin
|
Life Sciences |
Enzyme fermentation, Custom products and Bulk fermentation
|
Contract Manufacturing |
Bulk formulation, Sample collection kits, Private labelling, Molecular and forensic kits
|
Laboratory Testing |
Laboratory testing services certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. |